Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma

To determine the perceptions of US community-based hematologists/oncologists regarding approved CAR-T therapies in relapsed/refractory large B-cell lymphoma and barriers to their adoption in practice. In February and November 2019, US physicians with diverse geographic representation submitted respo...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2020-07, Vol.12 (10), p.725-732
Main Authors: Gajra, Ajeet, Jeune-Smith, Yolaine, Kish, Jonathan, Yeh, Ting-Chun, Hime, Skyler, Feinberg, Bruce
Format: Article
Language:English
Subjects:
access to care
Antigens
B-cell lymphoma
barriers to care
CAR-T cell therapy
Cell therapy
Chemotherapy
Chimeric antigen receptors
Classroom response systems
Hematology
large B-cell lymphoma
Lymphocytes
Lymphocytes B
Lymphocytes T
Lymphoma
Manufacturers
Medical referrals
Meetings
Mortality
Oncology
Patients
Physicians
Stem cells
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the perceptions of US community-based hematologists/oncologists regarding approved CAR-T therapies in relapsed/refractory large B-cell lymphoma and barriers to their adoption in practice. In February and November 2019, US physicians with diverse geographic representation submitted responses via a web-based survey prior to or via an audience response system at the live meetings. In February and November, 46 and 29% of physicians indicated that they had not referred any patients for CAR-T therapy, respectively. Cumbersome logistics, high cost and toxicity were defined as major barriers to prescribing CAR-T therapy. These findings highlight a need to improve processes, and address costs, to ensure timely access to this potentially curative therapy for relapsed/refractory large B-cell lymphoma patients.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2020-0118